kin-3248
kin-3248: sourced relationships with 1 company · 1 clinical trial tracked.
kin-3248 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could kin-3248 → KNTE affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| KINNATE BIOPHARMA INC. (KNTE) Solid Tumor, Adult | Phase 1 |
Clinical Trial Registry Records (1)
A Phase 1/1b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
Primary endpoint: Part A (dose escalation) - incidence of dose limiting toxicities (DLTs)
Frequently asked questions
Which companies have sourced relationships with kin-3248?
kin-3248 has dated SEC/FDA relationship records for KINNATE BIOPHARMA INC..
How many clinical trials involve kin-3248?
BioSniper tracks 1 clinical trial involving kin-3248.